SS&C GlobeOp Forward Redemption Indicator
WINDSOR, Conn.--(BUSINESS WIRE)-- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the SS&C GlobeOp Forward Redemption Indicator for May 2025 measured 2.34%, up from 1.85% in April.
'Recent favorable trends in asset retention indicate investors favor the strong risk-adjusted and uncorrelated returns provided by hedge funds," said Bill Stone, Chairman and Chief Executive Officer, SS&C Technologies.
Share
'SS&C GlobeOp's Forward Redemption Indicator for May 2025 was 2.34%. The figure represents a decrease in termination notices compared to the 2.78% reported for the same period a year ago,' said Bill Stone, Chairman and Chief Executive Officer, SS&C Technologies. 'Recent favorable trends in asset retention indicate investors favor the strong risk-adjusted and uncorrelated returns provided by hedge funds. These returns help investors mitigate the recent bouts of volatility in both equity and fixed income markets.'
The SS&C GlobeOp Forward Redemption Indicator represents the sum of forward redemption notices received from investors in hedge funds administered by SS&C GlobeOp on the SS&C GlobeOp platform, divided by the AuA at the beginning of the month for SS&C GlobeOp fund administration clients on the SS&C GlobeOp platform. Forward redemptions as a percentage of SS&C GlobeOp's assets under administration on the SS&C GlobeOp platform have trended significantly lower since reaching a high of 19.27% in November 2008. The next publication date is June 23, 2025.
Published on the 15th business day of the month, the SS&C GlobeOp Forward Redemption Indicator presents a timely and accurate view of the redemption pipeline for investors in hedge funds on the SS&C GlobeOp administration platform. Movements in the Indicator reflect investor confidence in their allocations to hedge funds. Indicator data is based on actual investor redemption notifications received. Unlike subscriptions, redemption notifications are typically received 30-90 days in advance of the redemption date. Investors may, and sometimes do, cancel redemption notices. In addition, the establishment and enforcement of redemption notices may vary from fund to fund.
SS&C GlobeOp Hedge Fund Performance Index
Base
Flash estimate (current month)
0.46%*
Year-to-date (YTD)
1.02%*
Last 12 month (LTM)
6.80%*
Life to date (LTD)
285.11%*
*All numbers reported above are gross
Expand
SS&C GlobeOp Capital Movement Index
Base
100 points on 31 December 2005
All time high
150.77 in September 2013
All time low
99.67 in January 2006
12-month high
125.72 in May 2024
12-month low
123.40 in January 2025
Largest monthly change
- 15.21 in January 2009
Expand
SS&C GlobeOp Forward Redemption Indicator
All time high
19.27% in November 2008
All time low
1.48% in April 2022
12-month high
3.54% in December 2024
12-month low
1.85% in April 2025
Largest monthly change
9.60% in November 2008
Expand
About the SS&C GlobeOp Hedge Fund Index®
The SS&C GlobeOp Hedge Fund Index (the Index) is a family of indices published by SS&C GlobeOp. A unique set of indices by a hedge fund administrator, it offers clients, investors and the overall market a welcome transparency on liquidity, investor sentiment and performance. The Index is based on a significant platform of diverse and representative assets.
The SS&C GlobeOp Capital Movement Index and the SS&C GlobeOp Forward Redemption Indicator provide monthly reports based on actual and anticipated capital movement data independently collected from all hedge fund clients for whom SS&C GlobeOp provides administration services on the SS&C GlobeOp platform.
The SS&C GlobeOp Hedge Fund Performance Index is an asset-weighted benchmark of the aggregate performance of funds for which SS&C GlobeOp provides monthly administration services on the SS&C GlobeOp platform. Flash estimate, interim and final values are provided, in each of three months respectively, following each business month-end.
While individual fund data is anonymized by aggregation, the SS&C GlobeOp Hedge Fund Index data will be based on the same reconciled fund data that SS&C GlobeOp uses to produce fund net asset values (NAV). Funds acquired through the acquisition of Citi Alternative Investor Services are integrated into the index suite starting with the January 2017 reporting periods. SS&C GlobeOp's total assets under administration on the SS&C GlobeOp platform represent approximately 10% of the estimated assets currently invested in the hedge fund sector. The investment strategies of the funds in the indices span a representative industry sample. Data for middle and back office clients who are not fund administration clients is not included in the Index, but is included in the Company's results announcement figures.
About SS&C Technologies
SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.
Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Why Applied Optoelectronics Stock Skyrocketed Today
Applied Optoelectronics stock rocketed higher Friday thanks to new financing disclosures from the company. The tech specialist announced that one of its subsidiaries had taken on a new loan that was used to pay a previously existing loan. News of the refinancing move follows an announcement that the company recently made a major product shipment to a hyperscaler customer. 10 stocks we like better than Applied Optoelectronics › Applied Optoelectronics (NASDAQ: AAOI) stock soared higher again in Friday's trading. The tech specialist's share price rose 18.6% in the daily session despite a 0.2% decline for the S&P 500 (SNPINDEX: ^GSPC) and a 0.5% fall for the Nasdaq Composite (NASDAQINDEX: ^IXIC). Applied Optoelectronics' valuation surged today thanks to news that one of the company's subsidiaries had reworked previously existing debt agreements. The stock climbed roughly 39% over the last week of trading. After the market closed on Wednesday, Applied Optoelectronics submitted a filing to the Securities and Exchange Commission (SEC) revealing two significant financing changes for its Global Technology subsidiary. Because the stock market was closed for the Juneteenth federal holiday on Thursday, the investor reaction to the new disclosures was pushed into today's trading. As per the filing with the SEC, Applied Optoelectronics' Global Technology has entered into a one-year credit agreement with China Construction Bank totaling 96.8 million Chinese renminbi -- which works out to roughly US$111.55 million based on the current exchange rate. Applied Optoelectronics said that the funding from the new agreement had been used to pay back other outstanding loans with Shanghai Pudong Development Bank. Despite this week's rally, Applied Optoelectronics stock is still down roughly 36% across the year due to uneven business performance and concerns about the company's financing. On the other hand, the company has recently announced significant shipments for its high-speed data center transceivers for a major data center customer. Along with some indications that the company could see an increase in demand powered by artificial intelligence (AI) initiatives from cloud hyperscaler customers, the recently announced financing moves suggest that the company has a found a near-term solution to some of its financing challenges. Before you buy stock in Applied Optoelectronics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Optoelectronics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Applied Optoelectronics Stock Skyrocketed Today was originally published by The Motley Fool
Yahoo
8 hours ago
- Yahoo
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company's next-generation cystic fibrosis treatment, Alyftrek. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. RBC Capital remains concerned about the gradual conversion compared to consensus expectations. Consequently, it has warned it could affect the company's operating margins by up to 2%. Nevertheless, the research firm insists that the company's cystic fibrosis franchise remains well-insulated from sector headwinds. However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current valuation in the market. Consequently, its reduced price target reflects lower year Alyftrek conversion rates. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops and commercializes therapies for serious diseases. They are known for their work in cystic fibrosis (CF) and are expanding into other areas like cell and genetic therapies. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform' Rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an 'Outperform' rating and a $49 price target. The research firm reiterated the company's solid position amid the 'TTR craze' while also echoing its commercial execution strategy. A medical technician wearing a lab coat operating machinery in a biopharmaceutical laboratory. Consequently, Wolfe Research expects BridegBio's revenue to total $569 million in 2025 before rising to $3.4 billion by 2028. It should peak at $4.4 billion in 2034. For the upcoming second quarter, the research firm expects the company to deliver revenue of $106 million, slightly below market expectation of $111 million. While the stock has shown a remarkable return of 42% year to date, Wolfe Research insists it must navigate several challenges to maintain the positive momentum. It must navigate the potential Vyndaqel loss of exclusivity, achondroplasia data versus competition, and pipeline products. In addition, consistent revenue growth and expanding operating margins will be crucial to the company's long-term success. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that develops and delivers transformative medicines for genetic diseases. Its pipeline includes a range of development programs, from early science to advanced clinical trials. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio
